National surveillance pilot study unveils a multicenter, clonal outbreak of VIM-2-producing *Pseudomonas aeruginosa* ST111 in the Netherlands between 2015 and 2017

Jannette Pirzadian1,56, Marjolein C. Persoon1,2,56, Juliëtte A. Severin3, Corné H. W. Klaassen1, Sabine C. de Greeff3, Marcel G. Mennen3,4, Annelot F. Schoffelen3, Cornelia C. H. Wielders1, Sandra Witteveen5, Marga van Santen-Verheuvel5, Leo M. Schouls5,57, Margreet C. Vos1,57 & the Dutch CPE surveillance Study Group*

Verona Integron-encoded Metallo-beta-lactamase (VIM) is the most frequently-encountered carbapenemase in the healthcare-related pathogen *Pseudomonas aeruginosa*. In the Netherlands, a low-endemic country for antibiotic-resistant bacteria, no national surveillance data on the prevalence of carbapenemase-producing *P. aeruginosa* (CPPA) was available. Therefore, in 2016, a national surveillance pilot study was initiated to investigate the occurrence, molecular epidemiology, genetic characterization, and resistomes of CPPA among *P. aeruginosa* isolates submitted by medical microbiology laboratories (MMLs) throughout the country. From 1221 isolates included in the study, 124 (10%) produced carbapenemase (CIM-positive); of these, the majority (95, 77%) were positive for the *bla*VIM gene using PCR. Sequencing was performed on 112 CIM-positive and 56 CIM-negative isolates (n = 168), and genetic clustering revealed that 75/168 (45%) isolates were highly similar. This genetic cluster, designated Group 1, comprised isolates that belonged to high-risk sequence type ST111/serotype O12, had similar resistomes, and all but two carried the *bla*VIM-2 allele on an identical class 1 integron. Additionally, Group 1 isolates originated from around the country (i.e. seven provinces) and from multiple MMLs. In conclusion, the Netherlands had experienced a nationwide, inter-institutional, clonal outbreak of VIM-2-producing *P. aeruginosa* for at least three years, which this pilot study was crucial in identifying. A structured, national surveillance program is strongly advised to monitor the spread of Group 1 CPPA, to identify emerging clones/carbapenemase genes, and to detect transmission in and especially between hospitals in order to control current and future outbreaks.

Carbapenemase-producing *Pseudomonas aeruginosa* (CPPA) is an emerging pathogen responsible for many serious healthcare-related infections worldwide1,2. Carbapenemases hydrolyze important antibiotics for treating *P. aeruginosa* infections, and frequently co-occur with other resistance mechanisms, resulting in a multidrug-resistant...
results from CIM tests and multiplex PCRs for all isolates included in the study are shown. From 1221 *P. aeruginosa* isolates that were included, 124 (10%) were CIM-positive. In 107 CIM-positive isolates, a carbapenemase gene was also detected. All *bla*<sub>KPC</sub> and *bla*<sub>CTX-M-48</sub> PCRs were negative, and are therefore not shown. In the right table, NGS results are shown. From the 124 CIM-positive isolates, 112 were sequenced, and the *bla*<sub>CIM</sub>-positive isolates, 112 were sequenced, and the *bla*<sub>CIM</sub>-positive alleles. Three isolates carried a *bla*<sub>VIM-2</sub> allele. Nine isolates carried a *bla*<sub>VIM-2</sub> allele. Seventeen CIM-positive isolates

### Table 1. Distribution of carbapenemase genes in CIM-positive *P. aeruginosa* isolates collected within the Netherlands between 2015 and 2017.

| Carbapenemase PCR | CIM-positive | Total Carbapenemase allele | CIM-negative |
|-------------------|--------------|----------------------------|--------------|
|                   | 2015 | 2016 | 2017 | Total | 2015 | 2016 | 2017 | Total |
| *bla*<sub>VIM</sub>-positive | 31 | 16 | 48 | 95 | *bla*<sub>VIM</sub>-2 | 19 | 16 | 48 | 83 |
| *bla*<sub>KPC</sub> | 3 | 2 | 4 | 9 | *bla*<sub>KPC</sub>-1 | 2 | 1 | 3 |
| *bla*<sub>IMP</sub> | 1 | 2 | 3 | 6 | *bla*<sub>IMP</sub>-1 | 1 | 1 | 2 |
| PCR negative | 4 | 8 | 5 | 17 | *bla*<sub>CIM</sub>-negative | 38 | 27 | 59 | 124 |
| Total | 38 | 27 | 59 | 124 | | 38 | 27 | 59 | 124 |

In the Netherlands, there is low endemicity for antibiotic-resistant bacteria. In 2018, only 2% of Dutch clinical *P. aeruginosa* isolates were MDR (i.e. resistant to ≥3 antimicrobial groups), but among MDR isolates, around 50% were phenotypically resistant to carbapenems. The first Dutch CPPA outbreak was reported in 2011 by one tertiary-care hospital; an investigation into isolates obtained between 2008 and 2009 that were resistant to imipenem revealed that 33% contained the *bla*<sub>VIM</sub> gene, and most belonged to a single genetic cluster. A surveillance study in 2012 based on convenience sampling, incorporating isolates from 2009 to 2011 and 21 medical microbiology laboratories (MMLs), similarly unveiled one large genetic cluster of VIM-2-producing *P. aeruginosa*. Among variants, the VIM-2 metallo-beta-lactamase exhibits the broadest geographical distribution, including on the European continent.

In 2016, a national surveillance pilot study was initiated by the National Institute for Public Health and the Environment (RIVM) in the Netherlands to determine the necessity of a structured surveillance program for CPPA. This was in addition to an existing surveillance program on carbapenemase-producing *Enterobacterales* that began in 2011; during that time, the RIVM had also coincidentally received *P. aeruginosa* isolates from several participating MMLs. In this study, *P. aeruginosa* isolates collected by the RIVM between 2015 and 2017 were analyzed to estimate the occurrence of CPPA among submitted isolates, characterize their genetic environment and molecular epidemiology using a whole-genome multilocus sequence typing (wgMLST) scheme, and determine their antibiotic resistance gene profiles.

### Results

#### CPPA occurrence among submitted isolates.

From January 2015 until December 2017, 39 Dutch MMLs submitted 1445 confirmed *P. aeruginosa* isolates with reduced sensitivity to meropenem and/or imipenem. These isolates were subjected to the carbapenemase inactivation method (CIM) to assess possible carbapenemase production. Only the first carbapenemase-producing (CIM-positive) and first non-carbapenemase-producing (CIM-negative) isolate per patient submitted during the study period were included, resulting in a total of 1221 isolates from 1216 patients, five of whom carried both a CIM-positive and CIM-negative *P. aeruginosa* isolate. For NGS, only a single isolate per patient was used.

Carbapenemase production was observed in 124 (10%) isolates using the CIM test; of these, 107 (86%) isolates were also positive for a carbapenemase gene using PCR (Table 1). All 1097 non-carbapenemase-producing isolates were also carbapenemase-PCR negative. The majority of CIM-positive isolates (77%, 95/124) carried a gene belonging to the *bla*<sub>VIM</sub> family. Analysis of next-generation sequencing (NGS) data on 83 CIM-positive, *bla*<sub>VIM</sub>-PCR-positive isolates revealed that they all carried the *bla*<sub>VIM-2</sub> allele. Nine isolates carried a *bla*<sub>IMP</sub> gene comprising five different *bla*<sub>IMP</sub> alleles. Three isolates carried a *bla*<sub>LIM-1</sub> allele. Seventeen CIM-positive isolates...
did not yield a PCR product, and were sequenced; three carried a blaGES-5 allele, but a carbapenemase-encoding gene could not be found in the remaining 14 isolates.

Sequencing revealed a large genetic cluster of blaVIM-2-containing CPPA. NGS was performed on 112 CIM-positive isolates, and on 56 CIM-negative isolates that were matched to CIM-positive isolates based on MML and sampling year. Demographic data provided by MMLs on the patients from which these isolates derived is available in Supplementary Table S1. In some regions, *P. aeruginosa* was not submitted or found, so isolates from these regions were not sequenced. A complete geographical overview of CIM-positive and CIM-negative isolates that were included is available in Supplementary Figure S1.

Genotypic relationships between isolates were determined using wgMLST (Fig. 1). There was a high degree of genotypic diversity, with large allelic distances often exceeding > 3500 alleles between isolates. However, 75/168 (45%) isolates were all CIM-positive (with the exception of one isolate), all belonged to sequence type ST111 and serotype O12, and all but two isolates carried the blaVIM-2 allele; one isolate carried blaIMP-13, and in the other, a CIM-negative isolate, no carbapenemase-encoding gene could be identified.

Within Group 1, several genetic clusters could be seen with few allelic differences between isolates. One CIM-negative isolate (also belonging to ST111/O12) was separated from Group 1 by only 95 allelic differences. All other isolates differed from Group 1 by > 3500 allelic differences. Group 1 also comprised isolates from seven Dutch provinces (Fig. 2).

The composition of the integron regions of six Group 1 isolates was reconstructed by combined short- and long-read sequencing. This showed that all four VIM-2-encoding Group 1 isolates contained an identical class 1 integron (Type A) carrying the *intI1* integrase gene, the blaVIM-2 gene flanked by the aminoglycoside resistance
genes aac(6′)-29a and aac(6′)-29b, an incomplete qacE gene involved in quaternary ammonium compound resistance, and the sulfonamide resistance gene sul1 (Fig. 3). In the CIM-negative Group 1 isolate, the blaVIM-2 and aac(6′)-29b genes were lost from this integron by deletion (Type B). The IMP-13-encoding Group 1 isolate was also shown to carry an integron (Type C) similar to the Type A integron, but contained the blaIMP-13 gene and the aminoglycoside resistance gene aac(6′)-Ib3. Mapping the Illumina reads of the other VIM-2-encoding Group 1 isolates against these reconstructed integrons showed that all carried the Type A integron.

**Group 1 isolates were distinct from internationally-derived CPPA isolates.** The wgMLST profiles of the 168 sequenced isolates in this study were compared to 260 complete, annotated P. aeruginosa chromosomal sequences from the National Center for Biotechnology Information’s GenBank database (Fig. 4). Group 1 is shown in the zoomed in panel; notably, the isolates sequenced in this study (blue circles) were interconnected and not interrupted by a different P. aeruginosa sequence (white circles). However, four isolates with the blaVIM-2 gene were closely related to Group 1, separated by only 3–66 allelic differences. The first strain (accession no. CP016955) was RIVM-EMC4982 from the Erasmus MC University Medical Center Rotterdam, which was the reference isolate used to design the wgMLST scheme for this study. The second strain, Carb01 63 (accession no. CP011317), originated from Maasstad Hospital, another hospital in Rotterdam, the Netherlands. The third strain, PA38182 (accession no. HG530068), originated from a hospital in the United Kingdom, and has been involved in several major outbreaks. The fourth strain, PaeAG1 (accession no. CP045739), was a MDR strain...
isolated from a patient with pneumonia admitted to intensive care in Costa Rica, and was the first strain reported to carry two carbapenemase-encoding genes (bla\textsuperscript{VIM-2} and bla\textsuperscript{IMP-18})\textsuperscript{16}. Five other GenBank isolates partitioned with Group 1 at larger distances (separated by 77–400 allelic differences). These isolates did not carry the bla\textsuperscript{VIM-2} gene, but one (accession no. LS998783) carried the carbapenemase-encoding gene bla\textsuperscript{GES-5}.

**Antibiotic resistance gene profiles and QRDR analysis.** ResFinder analyses showed that all 168 *P. aeruginosa* sequenced isolates carried the beta-lactamase gene bla\textsuperscript{PAO}, the aminoglycoside resistance gene aph(3')-IIb, and the fosfomycin resistance gene fosA (Supplementary Table S2). All but four isolates carried

---

**Figure 3.** Class 1 integron compositions of Group 1 isolates. All Group 1 isolates except two carried a 3554 bp Type A integron containing the bla\textsuperscript{VIM-2} gene cassette flanked by aac(6')-29a and aac(6')-29b genes. Yellow and green squares flanking the aac(6')-29a/b genes denote identical sequences. The integron structure of the CIM-negative Group 1 isolate was identical to a Type A integron, but the bla\textsuperscript{VIM-2} and aac(6')-29b genes had been deleted (Type B). The IMP-13-encoding Group 1 isolate carried a different gene cassette composition (Type C). P, promoter located within the integrase gene (intI1); aac(6')-29a, aac(6')-29b, and aac(6')-Ib3, aminoglycoside resistance genes; bla\textsuperscript{VIM-2} and bla\textsuperscript{IMP-13}, carbapenem resistance genes; qacEΔ, incomplete quaternary ammonium compound resistance gene; sul1, sulfonamide resistance gene. Figure was created using BioNumerics v7.6 and Adobe Illustrator 2020.

---

**Figure 4.** Minimum-spanning tree of the 168 *P. aeruginosa* isolates sequenced in this study (blue circles), and of 260 *P. aeruginosa* chromosomal sequences obtained from the NCBI GenBank database (white circles) based on wgMLST analysis. The enlarged portion of the tree displays Group 1 isolates, and the closely-related NCBI sequences with their accession numbers. The teal circle denotes the CIM-negative ST111/O12 isolate from this study that partitioned the closest to Group 1. The red circle indicates the Erasmus MC reference isolate that was used to design the wgMLST scheme. For understanding distances between isolates, refer to Fig. 1.
the chloramphenicol transferase gene catB7. Twenty-six other genes encoding beta-lactamase production, and 27 other genes associated with aminoglycoside resistance, were also found among the 168 isolates. The most prevalent beta-lactamase gene (56%, 94/168) was the bla_{OXA-58} gene. This gene was present in all Group 1 isolates, in 29% (11/38) of CIM-positive isolates that did not belong to Group 1, and in 15% (8/55) of CIM-negative isolates that did not belong to Group 1. Both aac(6’)-29a and aac(6’)-29b genes were found in all 73 VIM-2-encoding Group 1 isolates; only aac(6’)-29a was present in the CIM-negative Group 1 isolate, and neither gene was present in the IMP-13-encoding Group 1 isolate, confirming the integron compositions of Group 1 isolates after read-mapping. Among other isolates, one of either gene was found in three of the 38 CIM-positive isolates that did not belong to Group 1, but neither gene was found in any CIM-negative isolate that did not belong to Group 1.

An analysis of quinolone resistance-determining regions (QRDR) for genes gyrA, gyrB, parC, and parE in all sequenced isolates revealed that the gyrA T83I and the parC S87L mutations were found in 100% of ST111 isolates, but were also common among other sequence types; therefore, no unique mutation pattern could be determined for Group 1 isolates (Supplementary Table S3). The combination of T83I and D87N mutations in gyrA were only found in 60% (3/5) of ST175 isolates. The S87W mutation in parC was exclusively found in ST175 isolates.

**Discussion**

This national surveillance pilot study unveiled that the Netherlands had experienced an ongoing, nationwide, inter-institutional outbreak of a single, clonal genetic cluster of VIM-2-producing *P. aeruginosa* over a period of at least three years. It was clear from previous reports that several individual hospitals had already recognized this outbreak within their own settings. After the single-center CPPA outbreak reported by van der Bij et al., a surveillance study into 11 hospitals in the Netherlands in 2012 found that the outbreak by CPPA belonging to ST111 was widespread. The surprising results of that study, however, were not followed by the implementation of a structured, national surveillance program. The current study revealed that ST111/O12 has continued to prevail in the Netherlands, and that the outbreak has involved multiple MMLs distributed over a large part of the country.

RIVM has been asked to investigate if the reservoirs outside of healthcare institutions was not investigated during this study, community-acquired CPPA belonging to ST111/O12, the predominant *P. aeruginosa* lineage in Europe. Notably, Group 1 isolates were genetically distinct compared to the other sequenced isolates, exceeding 3500 allelic differences, and to most publicly-available sequences on GenBank. As *P. aeruginosa* strain Carb01 63 originated from the Netherlands and was isolated in 2012, the authors suspect that this strain also belonged to the outbreak described by this study. Like Carb01 63, Group 1 isolates belonged to sequence type ST111/O12, the predominant *P. aeruginosa* lineage in Europe.

*P. aeruginosa* ST111/O12 clones exhibit high morbidity and mortality in infected patients. ST111/O12 was first reported in the Netherlands in 2003, more than a decade before the inclusion period of this study, and then again in 2005. It is reasonable to suspect that the inter-institutional outbreak described by this study, and the multicenter outbreak described in 2012 by van der Bij et al., are linked, and may have started much earlier than previously anticipated. It is unclear when ST111/O12 was first introduced to the Netherlands, or how country-wide transmission could have occurred. Since it is known that patient referral networks can contribute to the spread of high-risk clones within a country, the transfer of patients between Dutch healthcare institutions most likely played a role in transmission, especially in cases of unnoticed colonization. To date, there have been no studies analyzing the impact of patient transfers between Dutch healthcare institutions. It is highly recommended that patient transfers include accompanying reports on colonization by highly-resistant microorganisms to limit potential inter-institutional transmission. In case of increasing prevalence rates encountered via a national surveillance system, an additional measure could be a national policy to screen patients for CPPA on admission. Screening should especially be performed in patients with a history of recent hospitalization in another healthcare center reporting a CPPA outbreak. Furthermore, CPPA, including ST111/O12 clones, have been shown to reside in the wet niches of hospitals through the formation of biofilm reservoirs. These reservoirs are persistent, may resist disinfection, and can disperse CPPA to vulnerable patient populations, so identifying and limiting environmental sources of ST111/O12 clones is of particular interest. ST111/O12 clones have also been found outside of hospitals in wastewater effluents, as the presence of CPPA reservoirs outside of healthcare institutions was not investigated during this study, community-acquired CPPA infections cannot be ruled out.

This study has some limitations. Firstly, no epidemiological data were collected, so no risk factors could be conclusively linked to the outbreak, and transmission events could not be identified. Secondly, MML compliance with submitting isolates was not checked. Thirdly, not all CPPA could be sequenced with the Illumina platform due to budgetary reasons, so it is possible that additional emerging genetic clusters had been missed among the other included isolates; selection bias was limited by sequencing all CPPA isolates received between 2016 and 2017, and sequencing a random selection of CPPA isolates that had been voluntarily submitted in 2015. Finally, long-read sequencing was only performed for six Group 1 isolates.

As a result of this national surveillance pilot study, MMLs have been advised to continue submitting *P. aeruginosa* isolates to the RIVM for NGS and surveillance. Only isolates with demonstrable carbapenemase production and/or a carbapenemase-encoding gene(s) have been requested. However, structured, national surveillance is still lacking in the Netherlands, since results from current CPPA surveillance are only reported in the Type-Ned database. National surveillance should include alerting the MMLs involved, and supporting epidemiological
investigations into possible transmission routes; this is especially important for new, emerging clones, such as a clone with \( \text{bla}_{GES-5} \). National surveillance should also collect epidemiological data so that risk factors can be assessed. Additionally, the RIVM developed an in-house wgMLST scheme for \( P. \text{aeruginosa} \) to investigate the clonality of submitted isolates for this study, but recently several other validated schemes were published that may aid surveillance and outbreak investigations.

In conclusion, the widespread distribution of Group 1 CPPA throughout the Netherlands went unnoticed for a period of at least three years, and this national surveillance pilot study was crucial in identifying the outbreak. Based on previous reports, it is likely that this inter-institutional outbreak started even earlier than previously anticipated. Therefore, the authors strongly recommend the implementation of a structured, national surveillance program in the Netherlands that incorporates wgMLST to monitor the spread of Group 1 CPPA, to identify emerging clones/carbapenemase genes, and to detect transmission in and especially between hospitals to control current and future outbreaks.

**Methods**

**Inclusion of isolates.** In 2016, all Dutch MMLs were sent a letter requesting that \( P. \text{aeruginosa} \) isolates be sent to the RIVM for a national surveillance pilot study. Criteria for submission were that isolates had a minimum inhibitory concentration of \( > 2 \mu g/ml \) for meropenem or \( > 4 \mu g/ml \) for imipenem (as determined by the MMLs preferred antimicrobial susceptibility method), and that one isolate per-person-per-year-per-lab was submitted. For each submitted isolate, MMLs were also requested to provide patient age, patient sex, sampling year, sampling site, and MML location in a secured, web-based database called Type-Ned.

During an existing surveillance program on carbapenemase-producing Enterobacterales that began before this study, the RIVM had also received \( P. \text{aeruginosa} \) isolates from several MMLs, so isolates received in 2015 were also considered. \( P. \text{aeruginosa} \) isolates submitted between January 1, 2015 to December 31, 2017 were characterized as follows: species level identification was confirmed using MALDI-TOF MS (Bruker Daltonik, Bremen, Germany), carbapenemase production was assessed using the CIM test, and the detection of \( \text{bla}_{VIM} \), \( \text{bla}_{NDM} \), \( \text{bla}_{KPC} \), \( \text{bla}_{OXA-48} \) and \( \text{bla}_{NMC} \) genes was performed using multiplex PCR with primers and conditions as previously described. CIM-positive \( P. \text{aeruginosa} \) isolates, and a subset of CIM-negative \( P. \text{aeruginosa} \) isolates matched by sampling year and MML, were subjected to sequencing.

**Whole-genome sequence analyses.** NGS was performed using Illumina HiSeq 2500 (Illumina, San Diego, CA, USA), resulting in reads with 125 bases length. De novo assembly was performed using CLC Genomics Workbench v9.5.3 (Qiagen Bioinformatics, Aarhus, Denmark), and contig sequences with a minimum length of 500 bp and at least 30× average read coverage per contig were used for further analyses. QDRR analysis was performed using the sequence extraction tool in BioNumerics v7.6 (Applied Maths, Sint-Martens-Latem, Belgium), in which extracted sequences were translated and aligned to identify coding sequence changes. Sequence types and serotypes were inferred from NGS data in SeqSphere v3.5.0 (Ridom, Münster, Germany) as well as PAST software from the Center for Genomic Epidemiology.

Identification of wgMLST alleles was performed in SeqSphere using an in-house wgMLST scheme comprising 6117 core genes and 325 accessory genes based on the fully sequenced and annotated \( P. \text{aeruginosa} \) strain RIVM-EMC4982 (accession no. CP016955). Allelic distances between isolates were calculated using BioNumerics v7.6. Genes absent in the sequenced isolates were ignored and not counted as allelic differences.

For long-read sequencing, the Oxford Nanopore protocol SQK-LSK108 (https://community.nanoporetech.com) and the expansion kit for native barcoding EXP-NBD104 was used. DNA was repaired using FFPE and end-repair kits (New England BioLabs, Ipswich, MA, USA), followed by ligation of barcodes with bead cleanup using AMPure XP (Beckman Coulter, Brea, CA, USA) after each step. Barcoded isolates were pooled, and sequencing adapters were added by ligation. The final library was loaded onto a MinION flow cell (MIN-106 R9.4.1). After a 48-h sequence run, base calling and de-multiplexing was performed using Albacore 2.3.1, and a single FASTA file per isolate was extracted from the FAST5 files using Poretools 0.5.1 (https://github.com/rrwick/poretools)34. Illumina and Nanopore data were used in a hybrid assembly performed by Unicycler v0.4.4 (https://github.com/rrwick/Unicycler)35.

Antibiotic resistance gene profiles were generated by using the ResFinder program v3.2, and the database available from the Center for Genomic Epidemiology website (https://bitbucket.org/genomicepidemiology/resfinder/src/master; accessed 08-05-2020)31. For resistance gene identification, a 90% identity threshold and a minimum length of 60% were used as criteria.

**Ethical statement.** The standard administrative procedure for carbapenemase-producing Enterobacterales was used to collect strains and demographic data. Patient identifiers provided by MMLs were encrypted and then stored in the Type-Ned database, ensuring patient privacy in accordance with General Data Protection Regulation. Ethical approval was not required.

**Data availability**

Sequence data on the isolates in this paper have been deposited in the European Nucleotide Archive under study accession number PRJEB39528 (https://www.ebi.ac.uk/ena/browser/view/PRJEB39528).

Received: 28 June 2021; Accepted: 29 September 2021
Published online: 25 October 2021
Acknowledgements
We are indebted to Prof. Jaap van Dissel, director of the Center for Disease Control, for supporting and stimulating this work. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author contributions
L.S. and M.V. designed and initiated the study. S.W. and M.S.V. conducted the experimental procedures. S.W., M.S.V., and L.S. analyzed sequencing data. J.P., M.P., J.S., C.K., S.G., M.M., A.S., C.W., L.S. and M.V. analyzed and interpreted all other data. J.P. wrote the manuscript. All study authors read and approved the final manuscript. Members of the Dutch CPE surveillance Study Group submitted isolates to the RIVM and approved the manuscript.

Competing interests
JS and CK received non-financial support from bioMérieux outside of this work. All other authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-00205-w.

Correspondence and requests for materials should be addressed to M.C.V.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021

the Dutch CPE surveillance Study Group

L. Bode1, A. Troelstra2, D. W. Notermans6, A. Maijer-Reuwer7, M. A. Leversteijn-van Hall8, J. A. J. W. Klyutmans9, I. J. B. Spijkerman10, K. van Dijk11, T. Halaby12, B. Zwart13, B. M. W. Diedereren14, A. Voss15, J. W. Dorigo-Zetsma16, A. Ott17, J. H. Oudbier18, M. van der Vusse19, A. L. M. Vlek20, A. G. M. Buiting21, S. Paltansing22, P. de Man22, A. J. van Griethuyzen23, M. van Reijs23, M. van Trijp25, E. P. M. van Elzakker26, A. E. Muller27, M. P. M. van der Linden28, M. van Rijn29, M. J. H. M. Wolfhagen30, K. Waar31, P. Schneeberger32, W. Silvis33, T. Schulin34, M. Damen35, S. Dinant36, S. P. van Mens36, D. C. Melles37, J. W. T. Cohen Stuart38, M. L. van Ogtrop39, I. T. M. A. Overdevest40, A. van Dam41, H. Wertheim42, H. M. E. Frénay43, J. C. Sinnige44, E. E. Mattsson45, R. W. Bosboom46, A. Stamat47, E. de Jong48, N. Roescher49, E. Heikens50, R. Steingrover51, E. Bathoorn52, T. A. M. Trienekens53, D. W. van Dam54, E. I. G. B. de Brauwere55 & F. S. Stals55

1Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. 2Department of Medical Microbiology, ADRZ Medical Center, Goes, The Netherlands. 3Department of Medical Microbiology, Alrijne Hospital, Leiden, The Netherlands. 4Microvida Laboratory for Microbiology, Amphia Hospital, Breda, The Netherlands. 5Department of Medical Microbiology, Amsterdam UMC (Location AMC), Amsterdam, The Netherlands. 6Department of Medical Microbiology and Infection Control, Amsterdam UMC (Location VUmc), Amsterdam, The Netherlands. 7Department of Medical Microbiology, Analytical Diagnostic Center N.V., Willemstad, Curaçao. 8Department of Medical Microbiology, Atalmedial, Amsterdam, The Netherlands. 9Department of Medical Microbiology, Bravis Hospital/ZorgSaam Hospital Zeeuws-Vlaanderen, Roosendaal/Terneuzen, The Netherlands. 10Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. 11Department of Medical Microbiology, CBSSL, Hilversum, The Netherlands. 12Department of Medical Microbiology, Certe, Groningen, The Netherlands. 13Department of Medical Microbiology, Deventer Hospital, Deventer, The Netherlands. 14Department of Medical Microbiology and Immunology, Diakonessenhuis, Utrecht, The Netherlands. 15Department of Medical Microbiology and
Immunology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands. 22Department of Medical Microbiology and Infection Prevention, Franciscus Gasthuis and Vlietland, Schiedam, The Netherlands. 23Department of Medical Microbiology, Gelderse Vallei Hospital, Ede, The Netherlands. 24Department of Medical Microbiology and Infection Prevention, Gelre Hospitals, Apeldoorn, The Netherlands. 25Department of Medical Microbiology and Infection Prevention, Groene Hart Hospital, Gouda, The Netherlands. 26Department of Medical Microbiology, Haga Hospital, ’s-Gravenhage, The Netherlands. 27Department of Medical Microbiology, HMC Westeinde Hospital, ’s-Gravenhage, The Netherlands. 28Department of Medical Microbiology, IJSselland Hospital, Capelle a/d IJssel, The Netherlands. 29Department of Medical Microbiology, Ikazia Hospital, Rotterdam, The Netherlands. 30Laboratory of Medical Microbiology and Infectious Diseases, Isala Hospital, Zwolle, The Netherlands. 31Department of Medical Microbiology, Izore Center for Infectious Diseases Friesland, Leeuwarden, The Netherlands. 32Department of Medical Microbiology and Infection Control, Jeroen Bosch Hospital, ’s-Hertogenbosch, The Netherlands. 33LabMicTA, Regional Laboratory of Microbiology Twente Achterhoek, Hengelo, The Netherlands. 34Department of Medical Microbiology, Laurentius Hospital, Roermond, The Netherlands. 35Department of Medical Microbiology, Maasstad Hospital, Rotterdam, The Netherlands. 36Department of Medical Microbiology, Maastricht University Medical Center, Maastricht, The Netherlands. 37Department of Medical Microbiology, Meander Medical Center, Amersfoort, The Netherlands. 38Department of Medical Microbiology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands. 39Department of Medical Microbiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. 40Department of Medical Microbiology, PAMM, Veldhoven, The Netherlands. 41Public Health Laboratory, Public Health Service, Amsterdam, The Netherlands. 42Department of Medical Microbiology and Infection Control, Regional Laboratory Medical Microbiology, Dordrecht, The Netherlands. 43Department of Medical Microbiology, Regional Laboratory of Public Health, Haarlem, The Netherlands. 44Department of Medical Microbiology, Reinier de Graaf Groep, Delft, The Netherlands. 45Laboratory for Medical Microbiology and Immunology, Rijnstate Hospital, Velp, The Netherlands. 46Department of Medical Microbiology, Saltro Diagnostic Center, Utrecht, The Netherlands. 47Department of Medical Microbiology, Slingeland Hospital, Doetinchem, The Netherlands. 48Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, The Netherlands. 49Department of Medical Microbiology, St. Jansdal Hospital, Harderwijk, The Netherlands. 50Department of Medical Microbiology, St. Maarten Laboratory Services N.V., Cay Hill, St. Maarten. 51Department of Medical Microbiology, University Medical Center Groningen, Groningen, The Netherlands. 52Department of Medical Microbiology, VieCuri Medical Center, Venlo, The Netherlands. 53Department of Medical Microbiology and Infection Control, Zuyderland Medical Center, Sittard-Geleen, The Netherlands. 54Department of Medical Microbiology and Infection Control, Zuyderland Medical Center, Heerlen, The Netherlands.